Compare · ANTX vs NVO
ANTX vs NVO
Side-by-side comparison of AN2 Therapeutics Inc. (ANTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $200.72B, about 958.4x ANTX ($209.4M).
- Both names hit the wire about 8 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 13 for ANTX).
- Company
- AN2 Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $5.67+1.71%
- $45.74+0.92%
- Market cap
- $209.4M
- $200.72B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 8
- 8
- Recent ratings
- 13
- 25
AN2 Therapeutics Inc.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ANTX
- AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
- SEC Form 3 filed by new insider Trenor Cameron C. Iii
- AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
- Director Readnour Robin Shane sold $212,702 worth of shares (35,402 units at $6.01) as part of a pre-agreed trading plan (SEC Form 4)
- Director Zakrzewski Joseph S gifted 405,880 shares (SEC Form 4)
- SEC Form 10-Q filed by AN2 Therapeutics Inc.
- AN2 Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
- Director Aziz Kabeer was granted 2,852 shares, increasing direct ownership by 5% to 59,106 units (SEC Form 4)
- Director Marks Gilbert Lynn was granted 2,789 shares, increasing direct ownership by 4% to 81,873 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S